|
Nemtabrutinib Clinical Trials
6 actively recruiting trials across 5 locations
No change since May 2026
Also known as: ARQ 531, ARQ-531, ARQ531, BTK Inhibitor ARQ 531, Bruton's Tyrosine Kinase Inhibitor ARQ 531 +1 more
Pipeline
Phase 2: 4Phase 3: 2
Top Sponsors
- Merck Sharp & Dohme LLC3
- Roswell Park Cancer Institute1
- Fred Hutchinson Cancer Center1
- City of Hope Medical Center1
Indications
- Cancer6
- Chronic Lymphocytic Leukemia2
- Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma1
- Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma1
- Waldenstroms Macroglobulinaemia1
Springdale, Arkansas2 trials
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Highlands Oncology Group ( Site 5405)
Phase 3
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Highlands Oncology Group ( Site 2728)
Phase 2
Mobile, Alabama1 trial
Duarte, California1 trial
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
City of Hope Medical Center
Phase 2
Buffalo, New York1 trial
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Roswell Park Cancer Institute
Phase 2
Seattle, Washington1 trial
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Fred Hutch/University of Washington Cancer Consortium
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.